Filament's botanical psilocybin drug candidate PEX010 to be administered in Germany for treatment-resistant depression
VANCOUVER, BC, July 31, 2025 /CNW/ - Filament Health Corp. (OTC:FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the first-ever approval for compassionate use of psilocybin in the European Union (EU). The Company's botanical psilocybin drug candidate, PEX010, has been authorized for administration to a patient suffering from treatment-resistant depression (TRD) in Germany.
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/International%20Business%20Machines%20Corp_%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
